Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $60 to $67.

February 28, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Apellis Pharmaceuticals and raises the price target from $60 to $67.
The increase in price target from $60 to $67 by a reputable analyst suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the analyst sees limited upside beyond the new target, balancing the impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100